Evidence Table M1. Articles/arms for class ANTI-ANDROGEN.

CompTrial Treatment Dose, route, frequency Comments, ancillary treatment

TARGET COMPARATOR Outcome

Table(s)

HEADING

Treatment Dose, route, frequency Comments, ancillary treatment

Applied with calibrated 

pipette. 

M.01.01 141 Cyproterone 20 mg topical qhs. Vehicle No dose information. Continuous

Combination pill is taken 

qd x 21 days, then 7 days 

off. 

M.01.02 245 Continuous

Discrete

Ethinyl 0.05 mg oral qd. 

estradiol

Cyproterone 2 mg oral qd. 

Minocycline 50 mg oral bid. 

hydrochloride

Cyproterone + ee: 21 days 

on then 7 days off. 

M.01.03 137 Continuous

Discrete

Placebo No dose information. 

Cyproterone 2 mg oral qd. 

Ethinyl 0.05 mg oral qd. 

estradiol

Tetracycline 500 mg oral (28d)

Placebo No dose information. 

OCP schedule: 2ld pills; 

7d placebo. 

Applied with calibrated 

pipette. 

M.01.04 141 Cyproterone 2 mg oral qd. Continuous

Ethinyl 0.035 mg oral qd. 

estradiol

Cyproterone 20 mg topical qhs. 

Frequency was not 

explicitly specified but 

presumably was qid. 

M.01.05 48 Continuous

Discrete

Ethinyl 0.05 mg oral qd. 

estradiol

Cyproterone 2 mg oral qd. 

Ethinyl 0.035 mg oral qd. 

estradiol

Cyproterone 2 mg oral qd. 

Frequency was not 

explicitly specified but 

presumably was qid. 

Continuous

Discrete

Ethinyl 0.05 mg oral qd. 

estradiol

Cyproterone 2 mg oral qd. 

Ethinyl 0.03 mg oral qd. 

estradiol

Levonorgestrel 150 mg oral qd. 

66 Continuous

Discrete

Ethinyl 0.05 mg oral qd. 

estradiol

Cyproterone 2 mg oral qd. 

Ethinyl 0.035 mg oral qd. 

estradiol

Cyproterone 2 mg oral qd. 

Cycle 21 days on treatment 

and 7 days no treatment; 

treatment began day 5 of 

menstrual cycle. 

Cycle 21 days on 

treatment and 7 days 

no treatment; treatment 

began day 5 of 

menstrual cycle. 

117 Ethinyl 0.05 mg oral qd. Continuous

estradiol

Cyproterone 2 mg oral qd. 

Ethinyl 0.035 mg oral qd. 

estradiol

Cyproterone 2 mg oral qd. 

Combo taken from days 5 -

25 of the cycle. 

Cyproterone was taken 

from days 5-14 of cycle 

inclusive ee was taken 

from days 5-25 of cycle 

inclusive. Followed 

reversed sequential 

regime of 

M.01.06 237 Continuous

Discrete

Ethinyl 0.05 mg oral qd. 

estradiol

Cyproterone 2 mg oral qd. 

Ethinyl 0.05 mg oral qd. 

estradiol

Cyproterone 0.05 mg oral qd. 

"(M)" indicates that data are found on the Multi-Arm tables. Evidence Table M HEADING: Page 1 of 4
CompTrial Treatment Dose, route, frequency Comments, ancillary treatment

TARGET COMPARATOR Outcome

Table(s)

HEADING

Treatment Dose, route, frequency Comments, ancillary treatment

Hammmerstein et al 

(1975). 

21 days tablets; 7 days no 

tablets. 

21 days tablets; 7 days 

no tablets. 

M.01.07 55 Continuous

Discrete

Ethinyl 0.03 mg oral qd. 

estradiol

Desogestrel 150 mg oral qd. 

Ethinyl 0.05 mg oral qd. 

estradiol

Cyproterone 2 mg oral qd. 

21 days: 2.0 mg 

cyproterone + 35 mg ee; 7 

days: no treatment. 

7 days: 0.025 mg 

desogestrol + 0.040 mg 

ee; 15 days: 0.125 mg 

desogestrol + 0.030 mg 

ee; 6 days: no 

treatment. 

87 Continuous

Discrete

Ethinyl 35 mg oral qd. 

estradiol

Cyproterone 2 mg oral qd. 

Ethinyl 0.035 mg oral qd. 

estradiol

Desogestrel No dose information. 

618 cycles; started day 1 of 

menstrual cycle; no 

definition of cycle. 

618 cycles; started day 

1 of menstrual cycle; 

no definition of cycle. 

103 Ethinyl 0.035 mg oral qd. Discrete

estradiol

Cyproterone 2 mg oral qd. 

Desogestrel 0.15 mg oral qd. 

Ethinyl 0.03 mg oral qd. 

estradiol

M.01.08 48 Continuous

Discrete

Ethinyl 0.035 mg oral qd. 

estradiol

Cyproterone 2 mg oral qd. 

Ethinyl 0.03 mg oral qd. 

estradiol

Levonorgestrel 150 mg oral qd. 

Cyproterone was taken 

from days 5-14 of cycle 

inclusive ee was taken from 

days 5-25 of cycle 

inclusive. Followed 

reversed sequential regime 

of Hammmerstein et al 

(1975). 

Placebo to resemble 

(cpa 50 mg tablets); 

combo preparation of 

norethisterone acetate 

1 mg + ee 50 mg taken 

days (5-25) of the 

cycle -inclusive and 

placebo taken from 

days 5-14 inclusive. 

M.01.09 237 Continuous

Discrete

Ethinyl 0.05 mg oral qd. 

estradiol

Cyproterone 0.05 mg oral qd. 

Ethinyl 0.05 mg oral qd. 

estradiol

Placebo No dose information. 

Norethisterone 1 mg oral qd. 

Qd x 9 cycles of 21 days 

each, with a 7 day 

treatment. 

Qd x 9 cycles of 21 

days each, with a 7 day 

treatment. 

M.02.01 225 Continuous

Discrete

Desogestrel 0.15 mg oral qd. 

Ethinyl 0.03 mg oral qd. 

estradiol

Gestodene 0.075 mg oral qd. 

Ethinyl 0.03 mg oral qd. 

estradiol

M.02.02 263 Ethinyl 0.03 mg oral () Discrete

estradiol

Desogestrel 0.15 mg oral ()

Ethinyl 0.03 mg oral ()

estradiol

Levonorgestrel 0.15 mg oral ()

264 Ethinyl 0.03 mg oral qd. Continuous

estradiol

Desogestrel 0.15 mg oral qd. 

Ethinyl 0.03 mg oral qd. 

estradiol

Levonorgestrel 0.15 mg oral qd. 

"(M)" indicates that data are found on the Multi-Arm tables. Evidence Table M HEADING: Page 2 of 4
CompTrial Treatment Dose, route, frequency Comments, ancillary treatment

TARGET COMPARATOR Outcome

Table(s)

HEADING

Treatment Dose, route, frequency Comments, ancillary treatment

M.03.01 132 100 mg oral (can't (M)

say)

Spironolactone Placebo No dose information. 

Following by placebo in 

second half of study. 

Followed by 

spironolactone in 

second half of study. 

249 Continuous

Discrete

Spironolactone 200 mg oral qd. Placebo No dose information. 

M.04.01 2 Delta-0.2%- 0.2 % topical bid. Discrete

chlormadione

Vehicle No dose information. 

1/4 inch of cream applied 

each application = 5 mg. 

M.04.02 2 Delta-5%- 5 mg topical bid. Discrete

chlormadione

Vehicle No dose information. 

1/4 inch of cream 

applied each 

application = 5 mg. 

M.04.03 2 Delta-0.2%- 0.2 % topical bid. Discrete

chlormadione

Delta-5%- 5 mg topical bid. 

chlormadione

Synthetic estrogen. 

Topical - varied.

M.04.04 19 15 mg oral (qd for 4 Topical - varied. Discrete

weeks, bid for 4 

weeks, tid for 4 

weeks)

16-epiestriol-3-

allyl ether

15 mg oral (qd for 4 

weeks, bid for 4 

weeks, tid for 4 

weeks)

Placebo

M.04.05 295 Epiestriol 2.5 mg/g topical qd. Vehicle No dose information. Discrete

Generic soap and shampoo. Generic soap and 

shampoo.

M.04.06 213 Continuous

Discrete

Inocoterone 10 % topical bid. 

acetate

Vehicle No dose information. 

21 days of active treatment 

followed by 7 days of 

inactive drug: 0.0180 for 7 

days; 0.215 for 7 days; 

0.250 for 7 days; 0 for 7 

days. 

M.04.09 218 Color-matched tablets. Continuous

Discrete

Inactive drug No dose information. 

Norgestimate 0.18 mg oral qd. 

Ethinyl 0.035 mg oral qd. 

estradiol

Placebo No dose information. 

180 mg 1-7 days; 215 mg 8-

14 days; 250 mg 15-21 

days. 

280 Continuous

Discrete

Norgestimate No dose information. 

Ethinyl 0.035 mg oral qd. 

estradiol

Placebo No dose information. 

Proprietary topical 

preparation containing 

mild antiseptic and 

peeling agents.

M.04.10 248 Quinestradol 1 mg oral qd. Placebo No dose information. Continuous

"(M)" indicates that data are found on the Multi-Arm tables. Evidence Table M HEADING: Page 3 of 4
CompTrial Treatment Dose, route, frequency Comments, ancillary treatment

TARGET COMPARATOR Outcome

Table(s)

HEADING

Treatment Dose, route, frequency Comments, ancillary treatment

100 u qd X 2w; then 50 u 

qd X 4 w; then 25 u qod x 6 

w. Cetrimide®, ultra-violet 

light, tetracycline.

Cetrimide®, ultraviolet light, tetracyline.

M.04.11 271 Serum 58 unit oral () Discrete

gonadotrophin

Placebo 58 units oral qd. 

1.6 g per day in "divided 

dose" - doesn't say how 

many. 

1.6 g per day in 

"divided dose" - doesn't 

say how many. 

N.06.01 156 Cimetidine 1.6 g oral (*) Cimetidine 1.6 g oral (*) Continuous (M)

"(M)" indicates that data are found on the Multi-Arm tables. Evidence Table M HEADING: Page 4 of 4